Laurion Capital Management LP Bellus Health Inc. Transaction History

Laurion Capital Management LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$7.14 - $8.53 $23.4 Million - $28 Million	3,281,614 Added 211.45%	4,833,580 $34.8 Million
Q4 2022 Feb 14, 2023	SELL	$8.22 - $10.76 $383,701 - $502,266	-46,679 Reduced 2.92%	1,551,966 $12.8 Million
Q3 2022 Nov 14, 2022	SELL	$8.95 - $12.0 $33.3 Million - $44.6 Million	-3,715,694 Reduced 69.92%	1,598,645 $16.9 Million
Q2 2022 Aug 15, 2022	BUY	$6.46 - $10.02 $1.94 Million - $3.01 Million	300,000 Added 5.98%	5,314,339 $49.1 Million
Q1 2022 May 16, 2022	BUY	$5.56 - $7.99 $7.06 Million - $10.1 Million	1,270,220 Added 33.93%	5,014,339 $34.5 Million
Q4 2021 Feb 14, 2022	BUY	$5.26 - $8.3 $5.96 Million - $9.4 Million	1,132,500 Added 43.36%	3,744,119 $30.1 Million
Q3 2021 Nov 15, 2021	SELL	$2.7 - $6.64 $1.09 Million - $2.67 Million	-402,000 Reduced 13.34%	2,611,619 $16 Million
Q2 2021 Aug 13, 2021	BUY	$3.11 - $4.61 $311,000 - $461,000	100,000 Added 3.43%	3,013,619 $9.37 Million
Q1 2021 May 14, 2021	BUY	$3.03 - $4.58 $8.53 Million - $12.9 Million	2,813,619 Added 2813.62%	2,913,619 $11.2 Million
Q4 2020 Feb 12, 2021	BUY	$2.27 - $3.3 $227,000 - $330,000	100,000 New	100,000 $306,000

128K

Ticker BLU
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 125,793,000
Description
BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. Th...

Get notified when there are updates to the investment portfolio of Laurion Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Laurion Capital Management LP with notifications on news.